Radiopharmaceuticals in neurological and psychiatric disorders

Current Clinical Pharmacology

Volumn 3, Issue 2, 2008, Pages 99-107

  Valotassiou, Varvara ^a   Wozniak, Greta ^a   Sifakis, Nikolaos ^b   Demokopoulos, Nikolaos ^c   Georgoulias, Panagiotis ^a,d  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c NIMTS HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

Disorders; Neurological; PET; Psychiatric; Radiopharmaceuticals; SPECT

Indexed keywords

6 FLUORODOPA F 18; BENZODIAZEPINE RECEPTOR; CITALOPRAM; CYSTEINE ETHYL ESTER TC 99M; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LEVODOPA; NEUROLEPTIC AGENT; OPIATE RECEPTOR; PRAMIPEXOLE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SELEGILINE; SEROTONIN 1A RECEPTOR; DIAGNOSTIC AGENT;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PERFUSION; CEREBROVASCULAR DISEASE; CHOLINERGIC SYSTEM; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; EARLY DIAGNOSIS; EPILEPSY; HUMAN; MENTAL DISEASE; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROLOGIC DISEASE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SENILE PLAQUE; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; ANIMAL; BRAIN; SCINTISCANNING;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 52049105454     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408784293679     Document Type: Review

References (101)

1. Costa DC. In: Ell PJ, Gambhir SS Eds, Nuclear Medicine in clinical diagnosis and treatment. New York, Churchill Livingstone 2004; 1235-46.
2. Jolliet Riant P, Tillement JP. Mechanisms of nutrient and drug transfer through the blood-brain barrier and their pharmacological changes. Encephale 1999; 25: 135-45.
3. Hawkins RA, Peterson DR, Vina JR. The complementary membranes forming the blood-brain barrier. IUBMB Life 2002; 54: 101-7.
4. Wolburg H, Lippoldta A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002; 38: 323-37.
5. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003; 5: 376-89.
6. Rowley M, Kulagowski JJ, Watt AP, et al. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J Med Chem 1997; 40: 4053-68.
7. van De Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 2001; 15: 273-86.
8. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 2002; 91: 1358-70.
9. Tanaka H, Mizojiri K. Drug-protein binding and blood-brain barrier permeability. J Pharmacol Exp Ther 1999; 288: 912-8.
10. Jolliet Riant P, Tillement JP. Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol 1999; 13:16-26.
11. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 2002; 64: 1355-74.
12. 99mTc-ECD). J Cereb Blood Flow Metab 1994; 14: 4-11.
13. Jacquier-Sarlin MR, Polla BS, Slosman DO. Oxidoreductive state: the major determinant for cellular retention of technetium-99m-HMPAO. J Nucl Med 1996; 37: 1413-6.
14. Maziere B, Halldin C. In: Ell PJ, Gambhir SS Eds, Nuclear Medicine in clinical diagnosis and treatment. New York, Churchill Livingstone 2004; 1295-329.
15. Pimlott SL. Radiotracer development in psychiatry. Nucl Med Commun 2005; 26: 183-8.
16. Fujita M, Innis RB. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds, Neuropsychopharmacology. The fifth generation of progress. Philadelphia, Lippincott Williams & Wilkins. 2002; 411-25.
17. Wong DF, Pomper MG. Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems. Mol Imaging Biol 2003; 5: 350-62.
18. Hom RK, Katzenellenbogen JA. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl Med Biol 1997; 24: 485-98.
19. Johannsen B, Pietzsch HJ. Development of technetium 99m-based CNS receptor ligands: have there been any advances? Eur J Nucl Med 2002; 29: 263-75.
20. Kung HF, Kung MP, Choi SR. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med 2003; 33: 2-13.
21. Camargo EE. Brain SPECT in Neurology and Psychiatry. J Nucl Med 2001; 42: 611-23.
22. Ichimyia A. Functional and structural brain imagings in dementia. Psychiatry Clin Neurosci 1998; 52: 223-5.
23. Pakrasi S, O'Brien JT. Emission tomography in dementia. Nucl Med Commun 2005; 26: 189-96.
24. Rowe CC. In: Ell PJ, Gambhir SS Eds, Nuclear Medicine in clinical diagnosis and treatment. New York, Churchill Livingstone 2004; 1371-85.
25. Woods SW. Regional cerebral blood flow imaging with SPECT in psychiatric disease: focus on schizophrenia, anxiety disorders and substance abuse. J Clin Psychiatry 1992; 53: 20-5.
26. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 1997; 349: 1735-9.
27. Musalek M, Podreka I, Walter H, et al. Regional brain function in hallucinations: a study of regional cerebral blood flow with 99m-Tc-HMPAO-SPECT in patients with auditory hallucinations, tactile hallucinations, and normal controls. Compr Psychiatry 1989; 30: 99-108.
28. Pilowsky L, Kerwin RW. In: Ell PJ, Gambhir SS Eds, Nuclear Medicine in clinical diagnosis and treatment. New York, Churchill Livingstone 2004; 1429-34.
29. Frankle GW, Laruelle M. Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 2002; 16: 437-46.
30. Larouelle M. Imaging dopamine transmission in schizophrenia. A review and meta analysis. Q J Nucl Med 1998; 42: 211-21.
31. Larouelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423-51.
32. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17: 162-74.
33. 2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001; 25: 213-23.
34. 11C) DOPA and PET. Biol Psychiatry 1999; 46: 681-8.
35. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002; 159: 761-7.
36. Maes M, Meltzer H. In: Bloom F, Kupfer D, Eds, Psychopharmacology: the fourth generation of progress. New York, Raven Press 1995; 933-44.
37. Bonvento G, Mackenzie E. In: Welch KMA, Ed, Primer on cerebrovascular diseases. New York, Academic Press 1997; 80-2.
38. Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry 1998; 44: 534-49.
39. Cooper J, Bloom F, Roth R. In: The biochemical basis of neuropharmacology. 7th ed. New York, Oxford University Press, 1996.
40. Owens M, Morgan W, Plott S, Nemeroff C. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283: 1305-22.
41. D'haenen H. Imaging the serotonergic system in depression. Eur Arch Psychiatry Clin Neurosci 2001; 251: 76-80.
42. Pirker W, Asenbaum S, Kasper S, et al. β-CIT SPECT demonstrates blockade of 5HT - uptake site by citalopram in the human brain in vivo. J Neural Transm Gen Sect 1995; 100: 247-56.
43. Jacobs B, Azmitia E. Structure and function of the brain serotonergic system. Physiol Rev 1992; 72: 165-229.
44. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000; 57: 174-80.
45. Shiue CY, Shiue GG, Mozley PD, et al. P-18F-MPPF: a potential radioligand for PET studies of 5-HT1A receptors in humans. Synapse 1997; 25: 147-54.
46. Jovkar S, Wienhard K, Coenen H, Pawlik G, Heiss W. Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-(2′-18F)fluoroethylspiperone and positron emission tomography. Eur J Nucl Med 1991; 18: 158-63.
47. 18F]fluoroethylketanserin and PET. Neurosci Lett 1991; 123: 23-6.
48. 18F]RP62203: a selection 5-HT2A receptor radioligand for positron emission tomography. Nucl Med Biol 1996; 23: 169-71.
49. 2 receptors in humans using positron emission tomography. Eur J Nucl Med 1994; 21: 937-46.
50. 123I-5-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects. Eur J Nucl Med 1997; 24: 119-24.
51. 2A receptors with carbon-11-MDL 100,907. J Nucl Med 1997; 39: 208-14.
52. Petit-Taboue M, Landeau B, Osmont A, Tillet I, Barre L, Baron J. Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. J Nucl Med 1996; 37: 95-104.
53. 2 receptor agent. Nucl Med Biol 1997; 24: 295-303.
54. Diksic M, Nagahiro S, Sourkes T, Yamamoto Y. A new method to measure brain serotonin synthesis in vivo. I. Theory and basic data for a biological model. J Cereb Blood Flow Metab 1990; 10: 1-12.
55. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000; 47: 3-10.
56. Brucke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000; 247: 2-7.
57. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000; 247: 11-8.
58. Otsuka M, Ichiya Y, Kuwabara Y, et al. Differences in the reduced 18F-dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 1996; 136: 169-73.
59. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57: 278-84.
60. Booij J, Tissingh G, Winogrodzka A, et al. Practical benefit of [123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71.
61. Piccini P. Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003; 18: 3-8.
62. 123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian subjects. Mov Disord 2001; 16: 124-30.
63. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105: 1213-28.
64. Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002; 17: 518-23.
65. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15: 503-10.
66. Innis RB, Marek K, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999; 14: 436-42.
67. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61.
68. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003; 18: 1415-23.
69. Mozley PD, Schneider JS, Acton PD, et al. Binding of 99mTcTRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000; 41: 584-9.
70. Kim HJ, Im JH, Yang SO, et al. Imaging and quantification of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997; 38: 1703-11.
71. Leenders KL. Significance of non-presynaptic SPECT tracer methods in Parkinson's disease. Mov Disord 2003; 18: 39-42.
72. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26: 171-82.
73. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C]raclopride and [11C]N-methylspiperone. J Nucl Med 2000; 41: 65-70.
74. Hierholzer J, Cordes M, Venz S, et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med 1998; 39: 954-60.
75. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism reduction by dopamine agonists but not L-dopa. J Nucl Med 1996; 37: 1112-5.
76. Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. J Clin Neurosci 2005; 12: 221-30.
77. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab 2002; 22: 1035-41.
78. Mathis CA, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE. Lipophilic 11C-labeled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease. J Label Cpd Radiopharm 2001; 44: 26-8.
79. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-19.
80. Agdeppa ED, Kepe V, Liu J, et al. 2-Dialkylamino-6-Acylmalononitrile Substituted Naphthalenes (DDNP Analogs): Novel Diagnostic and Therapeutic Tools in Alzheimer's Disease. Mol Imaging Biol 2003; 5: 404-17.
81. Agdeppa ED, Kepe V, Kiziloglu ZN, et al. FDDNP analogs as probes for plaques and tangles in Alzheimer's disease. J Nucl Med 2000; 41(Suppl): 25.
82. Shoghi-Jadid K, Small GV, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry 2002; 10: 24-35.
83. Agdeppa ED, Kepe V, Shoghi-Jadid K, et al. in vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: a case study. J Nucl Med 2001; 42(Suppl): 65.
84. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry 2001;49: 211-20.
85. Nordberg A, Amberla K, Shigeta M, et al. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis Assoc Disord 1998; 12: 228-37.
86. Nordberg A, Lundqvist H, Hartvig P, et al. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 1997; 8: 78-84.
87. A-Benzodiazepine Receptors. Mini Rev Med Chem 2004; 4: 909-21.
88. 3H] flumazenil binding to the GABAA receptor complex in vitro. Neuropharmacology 1995; 34: 1169-75.
89. Savic I, Thorell JO, Roland P. [C-11] flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia 1995; 36: 1225-32.
90. Szelies B, Weber-Luxenburger G, Pawlik G, et al. MRI-guided flumazenil- and FDG-PET in temporal lobe epilepsy. Neuroimage 1996; 3: 109-18.
91. Brinkmann BH, O'Brien TJ, Mullan BP, O'Connor MK, Robb RA, So EL. Subtraction ictal SPECT coregistered to MRI for seizure focus localization in partial epilepsy. Mayo Clin Proc 2000; 75: 615-24.
92. Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol 1995; 52: 314-17.
93. Busatto GF, Pilowsky LS, Costa DC, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiat 1997; 154: 56-63.
94. Verhoeff NPLG. In: Ell PJ, Gambhir SS Eds, Nuclear Medicine in clinical diagnosis and treatment. New York, Churchill Livingstone 2004; 1275-94.
95. Frost JJ: PET imaging of the opioid receptor: The early years. Nucl Med Biol 2001; 28: 509-13.
96. Zubieta JK, Smith YR, Bueller JA, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 2001; 293: 311-5.
97. Ravert HT, Mathews WB, Musachio JL, Scheffel U, Finley P, Dannals RF. [11C]-Methy1 4-[(3,4-dichlorophenyl)acetyl]-3- [(1-pyrrolidinyl)-methyl]-1-piperazinecarboxylate ([11C]GR89696): Synthesis and in vivo binding to kappa opiate receptors. Nucl Med Biol 1999; 26: 737-41.
98. Madar I, Lever JR, Kinter CM, et al. Imaging of delta opioid receptors in human brain by N1′-([11C]methyl)naltrindole and PET. Synapse 1996; 24: 19-28.
99. Bartenstein PA, Prevett MC, Duncan JS, Hajek M, Wieser HG. Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography. Epilepsy Res 1994; 18: 119-25.
100. Mayberg HS, Dannals RF, Ross CA, et al. Mu opiate receptor binding in depressed patients measured with PET and C-11-carfentanil. J Nucl Med 1991; 32: 1078.
101. Zubieta J, Gorelick D, Stauffer R, Ravert H, Dannals R, Frost J. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 1996; 2: 1225-9.